Newborn screening for fragile X syndrome

Area of Science:

• Genetics
• Public Health Policy
• Medical Screening

Background:

• Fragile X syndrome (FXS) is a genetic disorder with potential for early intervention.
• Newborn screening policies have evolved, with technological advancements enabling broader application.
• The feasibility of newborn screening for FXS is increasing with improved technologies.

Purpose of the Study:

• To evaluate the likelihood of the US public health system adopting newborn screening for fragile X syndrome.
• To contextualize FXS screening within the history and current practices of newborn screening.
• To explore arguments for and against implementing FXS newborn screening.

Main Methods:

• Historical analysis of newborn screening policies.
• Discussion of current newborn screening practices.
• Argumentation based on potential benefits and barriers to screening.

Main Results:

• Technically, newborn screening for FXS is achievable.
• Inexpensive and accurate screening technologies are anticipated in the near future.
• Potential barriers include the lack of a definitive medical treatment for FXS.

Conclusions:

• Early intervention services offer significant benefits to infants identified with FXS and their families.
• Arguments such as informed reproductive risk, medically necessary information, and consumer demand support FXS newborn screening.
• FXS serves as a model for addressing broader societal issues related to genetic disorder discovery and screening technologies.